Post-Stroke Cognitive Impairments and the Potential for Treatment with Cellex

Objective. To assess the neuropsychological characteristics of post-stroke cognitive impairments (PSCI) in the acute period of ischemic stroke (IS) and to evaluate the efficacy of Cellex. Materials and methods. Complex neuropsychological testing was performed in 288 patients in the acute period of IS. Cellex was used in addition to basal treatment in 30 patients at a dose of 0.1 mg (1 ml) s.c. for 10 days, with treatment being initiated in the hyperacute period. Results and discussion. Multifunctional PSCI was detected in 87% of the patients in the acute period of IS. Most patients showed impairments to attention, regulatory functions, speech, and memory. More than a third of patients showed multifunctional non-amnestic cognitive impairments. Monofunctional nonamnestic PSCI was encountered in 5.5% of cases. Isolated memory deficit was found in 2% of patients. Most elderly patients displayed PSCI, mostly the mixed variant. Isolated decreases in the rate or regulation of cognitive activity dominated among young and middle-aged patients, with one in four patients showing mixed cognitive impairments. A tendency to greater age was seen in patients with mixed-type PSCI. Analysis of the efficacy of Cellex in the acute period of IS showed that use was linked with improvements in cognitive status and the state of neurodynamic, regulatory, and visuospatial functions. The neurotrophic agent Cellex was effective in correcting PSCI in the acute period of IS.

http://ift.tt/2gX0hWW